Haemonetics announced today that it completed its previously announced acquisition of cardiology-focused medical device company OpSens. Boston-based Haemonetics first announced plans to buy OpSens for more than $250 million in October. Upon completion of the deal, the company acquired all outstanding shares at a fully diluted equity value of about $255 million. As a result, […]
Opsens
Haemonetics to acquire OpSens for more than $250M, expanding cardiology device portfolio
Haemonetics today announced a definitive agreement to acquire cardiology-focused technology developer OpSens. Boston-based Haemonetics will acquire all outstanding shares of Opsens for CAD $2.90 in an all-cash transaction that will have a fully diluted equity value of approximately $253 million USD. The transaction is expected to close by the end of January 2024. Opsens develops […]
